Goldman Sachs analysts removed Zai Lab (ZLAB) from the firm’s APAC Conviction List as part of its monthly update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Promising Clinical Results and Strategic Developments Drive Buy Rating for Zai Lab
- Zai Lab Secures RMB300 Million Debt Facility
- Zai Lab falls -6.9%
- Zai Lab’s Strategic Positioning and Competitive Edge in SCLC Treatment Justifies Buy Rating
- Zai Lab to wait on results of FORTITUDE-102 prior to regulatory filing